Abstract
Three direct oral anticoagulants (DOACs) – Rivaroxaban, Apixaban and Dabigatran – are available for the prevention of thrombembolic events in patients with non-valvular arial fibrillation (AF) [ [1] Heidbuchel H. Verhamme P. Alings M. et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013; 15: 625-651 Crossref PubMed Scopus (705) Google Scholar ]. DOACs are considered as a promising alternative to vitamin K antagonists (VKAs), since frequent laboratory tests are not required and food and drug interference is reduced [ 1 Heidbuchel H. Verhamme P. Alings M. et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013; 15: 625-651 Crossref PubMed Scopus (705) Google Scholar , 2 Bauer K.A. Pros and cons of new oral anticoagulants. Hematol Am Soc Hematol Educ Prog. 2013; 2013: 464-470 Crossref PubMed Scopus (166) Google Scholar ]. Improvement of patient adherence is therefore expected.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
